BioSkryb Genomics Secures Exclusive License to Breakthrough Methylation Patent to Enable the First Single-Cell Five-Base Genome

BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, today announced the execution of an exclusive license to a patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco (CZ Biohub SF) covering a method for combined single-cell DNA methylation and genome variation analyses. The invention originated at Stanford and enables simultaneous, high-resolution readouts of genomic variants and DNA methylation from the same single cell using a non-destructive workflow that preserves DNA integrity.